Investigating treatment patterns for neuropathic pain in China

Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China: A Retrospective, Database, Multi-center Study (ReTARdant)

This study looks at how patients in China with diabetic and chemotherapy-related nerve pain are being treated to find out what works best and what needs improvement.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Daiichi Sankyo (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 10 sites (Beijing and 9 other locations)
• Trial ID: NCT06546202 on ClinicalTrials.gov

What this trial studies

This observational study aims to explore the pharmacological treatment patterns among patients suffering from diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN) in China. It will gather real-world data on patient characteristics, clinical diagnoses, treatment patterns, and medication adherence from patients diagnosed between January 2018 and December 2021. The study seeks to identify unmet needs in the management of these conditions to better inform clinical decision-making for healthcare providers.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older diagnosed with DPNP or CIPN who have received targeted medication within the specified timeframe.

Not a fit: Patients with a history of epilepsy, schizophrenia, or bipolar disorder may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance treatment strategies for patients with neuropathic pain, leading to improved pain management and quality of life.

How similar studies have performed: While this study focuses on real-world data, similar studies have shown success in understanding treatment patterns for neuropathic pain, indicating a potential for valuable insights.

Eligibility criteria

Participants who meet all the following criteria will be included in the DPNP cohort.

1. Participants were diagnosed with diabetic neuropathy and presented with the pain symptom between 1st January 2018 and 31st December 2021;
2. Participants received at least one targeted medication between 1st January 2018 and 31st December 2021;
3. Participants were ≥18 years on the index date;
4. Participants had at least one medical visit record within 12 months after the index date

Participants who meet any one of the following criteria will be excluded from the DPNP cohort.

(1) Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date

Participants who meet all the following criteria will be included in the CIPN cohort.

1. Participants had neuropathy that was induced by the chemotherapy between 1st January 2018 and 31st December 2021, regardless of the presence of pain symptoms;
2. Participants received at least one targeted medication between 1st January 2018 and 31st December 2021;
3. Participants were ≥18 years on the index date;
4. Participants had at least one medical visit record within12 months after the index date

Participants who meet any one of the following criteria will be excluded from the CIPN cohort.

1. Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date;
2. Participants had neuralgia or neuropathy caused by tumor metastasis or non-chemotherapy-induced factors (e.g., radiotherapy, myasthenia gravis syndrome, paraneoplastic syndrome, direct tumor invasion, local tissue compression, postoperative traumatic pain, immune therapy-related pain, comorbidity-induced pain, etc.)

Where this trial is running

Beijing and 9 other locations

• China-Japan Friendship Hospital — Beijing, China (Recruiting)
• Beijing Hospital — Beijing, China (Not_yet_recruiting)
• Beijing Cancer Hospital — Beijing, China (Recruiting)
• The First Affiliated Hospital of Dalian Medical University — Dalian City, China (Recruiting)
• The First Affiliated Hospital of Fujian Medical University — Fuzhou City, China (Recruiting)
• Sun Yat-Sen University Cancer Center — Guangzhou City, China (Recruiting)
• Zhejiang Provincial People's Hospital — Hangzhou City, China (Recruiting)
• Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital) — Jinan City, China (Recruiting)
• Liaoning Cancer Hospital & Institute — Shenyang City, China (Recruiting)
• Tongji Hospital Tongji Medical College of Hust — Wuhan City, China (Recruiting)

Study contacts

• Study coordinator: Contact for Clinical Trial Information

Conditions Diabetic Peripheral Neuropathic Pain; Chemotherapy-induced Peripheral Neuropathy; Neuropathic Pain; Diabetic peripheral neuropathic pain; Chemotherapy-induced peripheral neuropathy; Neuropathic pain; Treatment pattern